drugset
Drugs / BCG SII
last change Oct 2024 re-read 2 minutes ago

BCG SII

also known as Bacille Calmette-Guérin Serum Institute of India

Vaccine

Developed for
tuberculosis
Investigated by
University of Oxford

Trials 1 · a red edge is where a trial was stopped

today NCT02380508 · not/applicable
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT02380508 Feb 2015 → Nov 2016 tuberculosis University of Oxford Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04351685 Comparator Nov 2020 → Oct 2024 tuberculosis Serum Institute of India Pvt. Ltd. Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as BCG SII ClinicalTrials.gov intervention name — accepted as the source's own label NCT04351685 ↗
1

NCT02380508 ↗
Known as Bacille Calmette-Guérin Serum Institute of India “Bacille Calmette-Guérin Serum Institute of India” NCT02380508 ↗
Modality Vaccine “Bacille Calmette-Guérin (BCG), the only currently licenced tuberculosis vaccine” PMID 35552463 ↗ May 2022
Route Other “administered intradermally” NCT04351685 ↗